Holen Sie sich die Stockscreener-App
28.67
4.71%
1.29
Vorhandelsmarkt:
28.56
-0.11
-0.38%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
Capricor: A Detailed Examination Of Hope-3 (NASDAQ:CAPR) - Seeking Alpha
Piper Sandler Reiterates Overweight Rating on CAPR, Raises Price Target | CAPR Stock News - GuruFocus
What Does the Market Think About Capricor Therapeutics Inc? - Benzinga
Biotech Stocks To Add to Your WatchlistDecember 5th - MarketBeat
A strong week for data readouts: Clinical Report - BioCentury
Capricor's cell therapy shows breakthrough results in Duchenne muscular dystrophy trial - Indian Pharma Post
Kennedy Capital Management LLC Reduces Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Oppenheimer Maintains Capricor Therapeutics (CAPR) Outperform Recommendation - Nasdaq
Oppenheimer raises Capricor Therapeutics price target to $54 on positive trial data - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 5.8%What's Next? - MarketBeat
Stock Traders Purchase High Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Oppenheimer Raises Capricor Therapeutics (CAPR) Price Target to $54 | CAPR Stock News - GuruFocus
Oppenheimer Adjusts Capricor Therapeutics PT to $54 From $22, Maintains Outperform Rating - marketscreener.com
Best Biotech Stocks To ConsiderDecember 7th - MarketBeat
Capricor Therapeutics launches proposed public offering of common stock - MSN
Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel - Seeking Alpha
Capricor Therapeutics prices $150M stock offering - MSN
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap UpShould You Buy? - MarketBeat
How Recent Developments Are Rewriting the Story for Capricor Therapeutics - Yahoo Finance
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular DystrophySlideshow (NASDAQ:CAPR) 2025-12-05 - Seeking Alpha
Capricor Therapeutics Announces $150 Million Public Offering - TradingView
CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know - The Globe and Mail
Capricor Therapeutics (CAPR) Stock :Prices $150M Offering for Next-Gen DMD Treatment Development - parameter.io
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap DownShould You Sell? - MarketBeat
Capricor Therapeutics sets pricing of $150 mln public offering of shares - marketscreener.com
Published on: 2025-12-05 06:37:44 - Newser
Capricor Therapeutics (CAPR) Surges After Pricing $150M Stock Of - GuruFocus
CAPR Collaborates with Managers for Successful Offering - GuruFocus
Can Capricor Therapeutics Inc. stock continue upward trendWeekly Profit Report & Consistent Return Strategy Ideas - Newser
Capricor Therapeutics Prices $150 Million Common Stock Offering; Shares Up Pre-Bell - marketscreener.com
Capricor Therapeutics prices public offering at $25 per share - Investing.com
Capricor Therapeutics prices public offering at $25 per share By Investing.com - Investing.com UK
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock - marketscreener.com
Why Capricor Therapeutics Inc. (4LN2) stock stays undervaluedMarket Rally & Weekly Stock Performance Updates - Newser
Is Capricor Therapeutics Still Attractive After Its 375% Surge in 2025? - simplywall.st
Geode Capital Management LLC Acquires 61,701 Shares of Capricor Therapeutics, Inc. $CAPR - MarketBeat
Why Capricor Therapeutics Inc. stock remains a top recommendationWeekly Trend Summary & Verified Momentum Stock Ideas - Newser
What insider trading reveals about Capricor Therapeutics Inc. stockJuly 2025 Weekly Recap & Stock Portfolio Risk Control - Newser
Inside Biotech: Capricor’s Duchenne results ignite a 500% surge — and an immediate equity raise - Proactive financial news
Capricor Therapeutics launches common stock offering By Investing.com - Investing.com South Africa
Maxim Group Maintains Capricor Therapeutics (CAPR) Buy Recommendation - Nasdaq
CAPR Stock Update: Piper Sandler and Oppenheimer Lead Offering - GuruFocus
Small Cap Stocks To ResearchDecember 3rd - MarketBeat
Capricor Therapeutics (CAPR) Launches Public Offering Amid Marke - GuruFocus
Capricor Therapeutics announces common stock offering, no amount given - TipRanks
Capricor Therapeutics Launches Proposed Public Stock Offering - marketscreener.com
Capricor Therapeutics launches common stock offering - Investing.com
Capricor Therapeutics launches equity offering following stock surge - TradingView
Capricor Therapeutics Announces Proposed Public Offering of Common Stock - The Manila Times
Capricor Therapeutics (NASDAQ: CAPR) plans stock offering to fund product development - Stock Titan
CAPR: Maxim Group Raises PT to $50, Maintaining Buy Rating | CAP - GuruFocus
Promising Biotech Stocks To ConsiderDecember 3rd - MarketBeat
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Capricor Therapeutics (NASDAQ:CAPR) Hits New 52-Week HighStill a Buy? - MarketBeat
Capricor Therapeutics price target raised to $50 from $25 at Maxim - TipRanks
HOPE On The Horizon For Capricor; To Submit Response To Complete Response Letter - RTTNews
Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Is Capricor Therapeutics Inc. (4LN2) stock cheap vs fundamentalsEarnings Performance Report & Free Low Drawdown Momentum Trade Ideas - Newser
Jaw dropping shares leap for Capricor on positive trial for deramiocel in DMD - The Pharma Letter
What insider purchases suggest about Capricor Therapeutics Inc. (4LN2) stockM&A Rumor & Safe Entry Zone Identification - Newser
Capricor Therapeutics shares fall 8.4% premarket after nearly five-fold jump in previous session - marketscreener.com
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):